Trials / Completed
CompletedNCT05362786
Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Chronic Kidney Disease
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- LaTonya J. Hickson · Academic / Other
- Sex
- All
- Age
- 30 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and tolerability of intravenously delivered mesenchymal steml cells (MSC) in one of two fixed dosing regimens at two time points in patients with chronic kidney disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Allogeneic adipose-derived mesenchymal stem cells (MSC) | Two intravenous infusions delivered systemically through a peripheral IV(over 30 minutes to 2 hours) of 100x10\^6 cells at day 0 and day 84 |
| DRUG | Allogeneic adipose-derived mesenchymal stem cells (MSC) | Single intravenous infusion delivered systemically through a peripheral IV(over 30 minutes to 2 hours) of 200x10\^6 cells at day 0 |
Timeline
- Start date
- 2022-07-01
- Primary completion
- 2024-07-24
- Completion
- 2024-07-24
- First posted
- 2022-05-05
- Last updated
- 2024-08-19
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05362786. Inclusion in this directory is not an endorsement.